WO2007038435A3 - Estriol therapy for autoimmune and neurodegenerative diseases and disorders - Google Patents

Estriol therapy for autoimmune and neurodegenerative diseases and disorders Download PDF

Info

Publication number
WO2007038435A3
WO2007038435A3 PCT/US2006/037259 US2006037259W WO2007038435A3 WO 2007038435 A3 WO2007038435 A3 WO 2007038435A3 US 2006037259 W US2006037259 W US 2006037259W WO 2007038435 A3 WO2007038435 A3 WO 2007038435A3
Authority
WO
WIPO (PCT)
Prior art keywords
autoimmune
disorders
neurodegenerative diseases
estriol
mediated
Prior art date
Application number
PCT/US2006/037259
Other languages
French (fr)
Other versions
WO2007038435A2 (en
Inventor
Rhonda R Voskuhl
Original Assignee
Univ California
Rhonda R Voskuhl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Rhonda R Voskuhl filed Critical Univ California
Priority to AU2006294826A priority Critical patent/AU2006294826A1/en
Priority to CA002623905A priority patent/CA2623905A1/en
Priority to US11/992,558 priority patent/US20120014915A9/en
Priority to JP2008533482A priority patent/JP2009510070A/en
Priority to EP06815340A priority patent/EP1928468A4/en
Publication of WO2007038435A2 publication Critical patent/WO2007038435A2/en
Publication of WO2007038435A3 publication Critical patent/WO2007038435A3/en
Priority to US13/722,672 priority patent/US20130203722A1/en
Priority to US14/333,027 priority patent/US20150051178A1/en
Priority to US15/685,156 priority patent/US10610535B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases) and more particularly. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these ThI -mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period.
PCT/US2006/037259 2001-04-25 2006-09-26 Estriol therapy for autoimmune and neurodegenerative diseases and disorders WO2007038435A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2006294826A AU2006294826A1 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerative diseases and disorders
CA002623905A CA2623905A1 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerative diseases and disorders
US11/992,558 US20120014915A9 (en) 2001-04-25 2006-09-26 Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders
JP2008533482A JP2009510070A (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerative diseases and disorders
EP06815340A EP1928468A4 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerative diseases and disorders
US13/722,672 US20130203722A1 (en) 2006-09-26 2012-12-20 Estriol therapy for autoimmune and neurodegenerative disease and disorders
US14/333,027 US20150051178A1 (en) 2001-04-25 2014-07-16 Estriol therapy for autoimmune and neurodegenerative diseases and disorders
US15/685,156 US10610535B2 (en) 2005-09-26 2017-08-24 Diarylpropionitrile therapy for treatment of multiple sclerosis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72097105P 2005-09-26 2005-09-26
US60/720,971 2005-09-26
US83352706P 2006-07-26 2006-07-26
US60/833,527 2006-07-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/151,040 Continuation-In-Part US8372826B2 (en) 2001-04-25 2005-06-13 Estriol therapy for multiple sclerosis and other autoimmune diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/992,558 A-371-Of-International US20120014915A9 (en) 2001-04-25 2006-09-26 Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders
US13/722,672 Continuation US20130203722A1 (en) 2001-04-25 2012-12-20 Estriol therapy for autoimmune and neurodegenerative disease and disorders

Publications (2)

Publication Number Publication Date
WO2007038435A2 WO2007038435A2 (en) 2007-04-05
WO2007038435A3 true WO2007038435A3 (en) 2007-06-28

Family

ID=37900361

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/037259 WO2007038435A2 (en) 2001-04-25 2006-09-26 Estriol therapy for autoimmune and neurodegenerative diseases and disorders

Country Status (5)

Country Link
EP (1) EP1928468A4 (en)
JP (1) JP2009510070A (en)
AU (1) AU2006294826A1 (en)
CA (1) CA2623905A1 (en)
WO (1) WO2007038435A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120328566A9 (en) * 2001-04-25 2012-12-27 Rhonda R Voskuhl Estrogen receptor ligand treatment for neurodegenerative diseases
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
EP2698167A3 (en) * 2005-09-26 2014-03-05 The Regents of The University of California Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis
EP2164498A4 (en) 2007-06-04 2010-09-08 Univ California Pregnancy hormone combination for treatment of autoimmune diseases
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
US10369158B2 (en) 2014-04-28 2019-08-06 The Regents Of The University Of California Pharmaceutical packaging for estriol therapy
US10799512B2 (en) 2014-04-28 2020-10-13 The Regents Of The University Of California Estrogen combination for treatment of multiple sclerosis
EP3782616B1 (en) 2014-09-02 2023-11-01 The Regents of The University of California Estrogen receptor ligand treatment for neurodegenerative diseases
WO2016036719A1 (en) 2014-09-02 2016-03-10 The Regents Of The University Of California Estrogen therapy for brain gray matter atrophy and associated disability
US9962395B2 (en) 2014-09-29 2018-05-08 The Regents Of The University Of California Compositions and methods for maintaining cognitive function
US10406169B2 (en) 2015-03-30 2019-09-10 The Regents Of The University Of California Methods of monitoring estriol therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
SE9502921D0 (en) * 1995-08-23 1995-08-23 Astra Ab New compounds
US6265147B1 (en) * 1999-12-01 2001-07-24 The Board Of Trustees Of The Leland Stanford Junior University Method of screening for neuroprotective agents
AU2002237126A1 (en) * 2001-03-02 2002-09-19 Stem Cell Therapeutics Inc. Use of ovarian hormone for increasing neural stem cell number
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
JP4801868B2 (en) * 2002-02-25 2011-10-26 晃史 山口 Systemic lupus erythematosus disease suppressant
EP2698167A3 (en) * 2005-09-26 2014-03-05 The Regents of The University of California Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GALEA ET AL.: "Estradiol alleviates depressive-like symptoms in novel animal model of post-partum depression", BEHAVIOURAL BRAIN RESEARCH, vol. 122, no. 1, 2001, pages 1 - 9, XP008082590 *
HALL G.L. ET AL.: "Beta-interferon and multiple sclerosis", TRENDS OF NEUROSCIENCE, vol. 20, 1997, pages 63 - 67, XP003014828 *
JANSSON L. ET AL.: "Estrogen indues a potent suppression of experimental autoimmune encephalomyelities and collagen-induced arthritis in mice", JOURNAL OF NEUROIMMUNOLOGY, vol. 53, no. 2, 1994, pages 203 - 207, XP001026625 *
KIM S. ET AL.: "Estriol ameliorates autoimmune demyelinating disease", NEUROLOGY, vol. 52, no. 6, 1999, pages 1230 - 1236, XP001026663 *
See also references of EP1928468A4 *

Also Published As

Publication number Publication date
CA2623905A1 (en) 2007-04-05
EP1928468A2 (en) 2008-06-11
EP1928468A4 (en) 2010-12-08
WO2007038435A2 (en) 2007-04-05
AU2006294826A1 (en) 2007-04-05
JP2009510070A (en) 2009-03-12

Similar Documents

Publication Publication Date Title
WO2007038435A3 (en) Estriol therapy for autoimmune and neurodegenerative diseases and disorders
WO2007038636A3 (en) Estriol therapy for autoimmune and neurodegenerataive diseases and disorders
Reddy Pharmacology of endogenous neuroactive steroids
WO2006037016A3 (en) Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
WO2007144152A3 (en) Extended step-down estrogen regimen
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
EP1558220A4 (en) Oral compositions for treatment of diseases
WO2004080413A3 (en) Uses and formulations for transdermal or transmucosal application of active agents
WO2005082382A8 (en) Formulations of thiomolybdate or thiotungstate compounds and uses thereof
WO2011049948A4 (en) Neuroprotection and myelin repair using nestorone®
IN2012DN04867A (en)
WO2006095029A3 (en) Di-polymer protein conjugates and processes for their preparation
Huber et al. Treating acne with oral contraceptives: use of lower doses
WO2007123848A3 (en) Therapeutic compositions containing modified class i slrp proteins
AR049112A1 (en) COMPOSITIONS, METHODS AND KIT, FOR THE TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER
WO2008008359A3 (en) Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor
WO2004017904A3 (en) Corticosteroid conjugates and uses thereof
TW200801031A (en) Steroid nitrooxyderivatives
EP2275109A3 (en) Pregnane steroids for use in the treatment of CNS disorders
WO2002014343A8 (en) Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
Ugale et al. Essentiality of central GABAergic neuroactive steroid allopregnanolone for anticonvulsant action of fluoxetine against pentylenetetrazole-induced seizures in mice
WO2006096404A3 (en) Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues
WO2006029040A3 (en) Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
EP2687215A1 (en) Mesterolone pharmaceutical composition for androgens' deficiencies in woman

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11992558

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2623905

Country of ref document: CA

Ref document number: 2008533482

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006815340

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006294826

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006294826

Country of ref document: AU

Date of ref document: 20060926

Kind code of ref document: A